To print: Select File and then Print from your browser's menu

Title: New Analysis of CHARM Programme Provides Key Insights into Patient Adherence to Heart Failure Medication

"New Analysis of CHARM Programme Provides Key Insights into Patient Adherence to Heart Failure Medication"

Data Adds to Growing Body of Evidence that Adherence Can Reduce the Risk of Death and Hospitalisation MÖLNDAL, SWEDEN -- December 7, 2005 -- AstraZeneca today announced that the December 10th issue of The Lancet published results of an analysis of the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) Programme, which demonstrated that adherence to medication in heart failure patients resulted in a lower risk of death compared with patients who did not take their medication as prescribed. "The new CHARM Programme analysis advances current knowledge about the effect that adherence to medication has on clinical outcomes in heart failure patients," said lead author Dr. Bradi B. Granger of Duke University Medical Center and Duke University School of Nursing. "By educating their patients on the importance of adherence, healthcare professionals have the opportunity to help improve the management of heart failure patients, thus increasing their chances for survival." The analysis included 7599 heart failure patients randomly assigned to Atacand® (candesartan cilexetil), an angiotensin II receptor blocker (ARB), or placebo. For all patients, good adherence was associated with lower all-cause mortality (HR 0.65, 95% CI 0.58-0.76, P <.001) and fewer hospital admissions for heart failure. Overall, 89% of patients were at least 80% adherent (defined as having taken blinded study medication as prescribed), and adherence was similar for patients taking Atacand and patients taking placebo. The analysis also identified several factors associated with poor adherence, including female gender, smoking, higher heart rate and more comorbid conditions1. "Although numerous studies have shown that medications and lifestyle modifications reduce the risk of mortality for heart failure patients, adherence to these regimens is often below optimum," Dr Anders Svensson, VP, External Scientific Affairs, Cardiovascular at AstraZeneca commented. "A number of barriers exist which prevent physicians incorporating the latest evidenced-based ESC guidelines to helping improve patient adherence to treatment. AstraZeneca is committed to support doctors in their aim to improve the management of heart failure." Previously presented data from the CHARM Programme, demonstrates a significant reduction in deaths and CHF hospital admissions in favour of Atacand®. A pre-specified analysis in the group of CHARM patients with heart failure and reduced LVEF (n=4576; LVEF

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.